BBIO vs EXEL
BridgeBio Pharma, Inc. and Exelixis, Inc., both Healthcare
BridgeBio Pharma, Inc. is the larger company at $14B against $13B. Over the past year EXEL returned +49% against +25% for BBIO. The RyuScore puts EXEL ahead, 80 against 7 out of 100.
| Figure | BBIO | EXEL |
|---|---|---|
| Last close | $65.35 | $59.86 |
| Market cap | $14B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 18.8 |
| 1-year return | +25% | +49% |
| 5-year return | +34% | +197% |
| RyuScoresector-relative, 1–10 | 7/100 | 80/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Exelixis, Inc.
Revenue of $629M in Q2 2026, net income $212M. Its largest reported line is Product Gross, 87% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.